Wall Street await Palatin Technologies, Inc. (NYSEMKT:PTN) to release earnings on February, 12. Analysts forecast earnings per share of $-0.07, down exactly $0.10 or 333.33% from 2014’s $0.03 EPS. After releasing $-0.08 EPS for the previous quarter, Palatin Technologies, Inc.’s analysts now forecasts -12.50% EPS growth. The stock decreased 3.77% or $0.02 on February 10, hitting $0.51. Palatin Technologies, Inc. (NYSEMKT:PTN) has declined 41.38% since July 8, 2015 and is downtrending. It has underperformed by 31.86% the S&P500.
The institutional sentiment decreased to 1.2 in Q3 2015. Its down 3.30, from 4.5 in 2015Q2. The ratio turned negative, as 4 funds sold all Palatin Technologies, Inc. shares owned while 6 reduced positions. 4 funds bought stakes while 8 increased positions. They now own 16.31 million shares or 46.36% less from 30.41 million shares in 2015Q2.
Sphera Funds Management Ltd. holds 0.35% of its portfolio in Palatin Technologies, Inc. for 3.36 million shares. Qvt Financial Lp owns 4.98 million shares or 0.1% of their US portfolio. Moreover, Broadfin Capital Llc has 0.06% invested in the company for 1.37 million shares. The New York-based Deerfield Management Co has invested 0.06% in the stock. Highlander Capital Management Llc, a New Jersey-based fund reported 67,500 shares.
Palatin Technologies, Inc. is a biopharmaceutical firm that develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. The company has a market cap of $34.05 million. The Company’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It currently has negative earnings. The Company’s primary product in clinical development is Bremelanotide, which is used for the treatment of female sexual dysfunction .